Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen a breakthrough therapy designation.
from Latest articles from Cancer Therapy Advisor News https://ift.tt/2vOiLwa
from Latest articles from Cancer Therapy Advisor News https://ift.tt/2vOiLwa